Aurobindo Pharma Limited reported a 32% year-on-year increase in consolidated net profit to ₹10.33 billion for the quarter ended June 30, 2026, driven by robust revenue growth and the recent acquisition of Lannett Company LLC. Consolidated revenue from operations rose to ₹91.5 billion compared to ₹77.9 billion in the same quarter last year. The Board of Directors, meeting on August 5, 2026, also approved a Scheme of Amalgamation to merge two step-down subsidiaries, Eugia Steriles Private Limited and Eugia SEZ Private Limited, into wholly-owned subsidiary Eugia Pharma Specialities Limited, aiming to simplify the corporate structure and reduce overheads.

The Board approved the standalone and consolidated unaudited financial results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Deloitte Haskins & Sells issued an unmodified conclusion on the limited review of the interim financial information. The merger proposal was disclosed under Regulation 30 of the SEBI LODR Regulations, with the scheme to be filed with the Hon'ble NCLT, Hyderabad. The transaction is classified as a related party transaction but is exempt from related party provisions under Section 188 of the Companies Act, 2013, as it involves wholly-owned subsidiaries.

Financial Performance Highlights

The company's consolidated financial results reflect strong operational momentum, with EBITDA expanding significantly on a year-on-year basis. The following table summarises key consolidated metrics:

Standalone revenue from operations stood at ₹27,995.1 million, a slight decline of 1.7% from ₹28,481.7 million in Q1FY25. However, standalone other income surged to ₹2,418.9 million from ₹837.7 million a year ago, largely due to higher foreign exchange gains. Total expenses decreased to ₹20,333.2 million from ₹21,818.5 million in the prior year period, contributing to the improved bottom line.

What the Numbers Show

The significant divergence between standalone and consolidated performance highlights the material impact of the Lannett Company LLC acquisition, completed on June 29, 2026. While standalone revenue dipped slightly, consolidated revenue and EBITDA both expanded meaningfully on a year-on-year basis, with EBITDA margin improving by 270 basis points to 23.07%. Exceptional items of ₹401.8 million were recorded in the consolidated statement for acquisition-related costs. The rise in other income, particularly foreign exchange gains of ₹526.2 million in the consolidated books versus nil in the prior year, further bolstered profitability.

Strategic Developments and Corporate Actions

The proposed amalgamation of Eugia entities aims to consolidate three companies engaged in manufacturing injectable pharmaceutical products into a single legal entity. This move is expected to eliminate duplicate corporate and administrative functions, reduce costs, and improve treasury management. The turnover for the involved entities for FY26 was as follows:

During the quarter, Aurobindo Pharma incorporated Arrow Pharma Production SAS in France and PT Auro Pharm Indonesia as step-down subsidiaries. The company also acquired a 26% stake in Swarnaakshu Solar Power Private Limited for ₹5.2 million. Subsequent to the quarter end, on July 23, 2026, subsidiary Apitoria Pharma Private Limited approved the acquisition of an 80% interest in the A1 Biochem Group for an enterprise value of USD 17.0 million.

Aurobindo Pharma Limited has disclosed the web-link to its Integrated Annual Report for the financial year ended March 31, 2026 (FY26), pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure precedes the company’s 39th Annual General Meeting (AGM) scheduled for Thursday, August 27, 2026, where shareholders will approve the audited financial statements and confirm an interim dividend of ₹4 per equity share.

The company notified the National Stock Exchange of India Limited and BSE Limited on August 4, 2026, that physical copies of the Annual Report have been sent only to members who have not registered email addresses with the company or depositories. For all other shareholders, the report is accessible via the company’s website or through a dedicated QR code. The disclosure ensures compliance with regulatory mandates for timely dissemination of financial information.

Key Disclosures and Shareholder Actions

Shareholders are advised to access the Integrated Annual Report 2025-26 through the following channels:

In addition to accessing the report, shareholders are urged to update their Know Your Customer (KYC) details, including PAN, postal address with pin code, email address, mobile number, bank account details, and nomination details. The Registrar and Transfer Agent (RTA), KFin Technologies Limited, has mandated that any payments, including dividends, for folios with incomplete KYC or PAN details will be made electronically only upon registration of the required information.

AGM and E-Voting Schedule

The 39th AGM will be conducted exclusively via Video Conferencing (VC) or Other Audio Visual Means (OAVM). The key dates for shareholder participation are as follows:

The Register of Members and Share Transfer Books will remain closed from August 26 to August 27, 2026. Institutional investors must submit board resolutions authorizing representatives to vote via email to the scrutinizer, M/s. RPR & Associates.

Governance and Auditor Updates

The AGM agenda includes the reappointment of Mr. K. Nithyananda Reddy and Dr. M. Madan Mohan Reddy, who retire by rotation. Additionally, the Board has recommended the appointment of M/s. RPR & Associates as the Secretarial Auditor for a term of five years, from FY27 to FY31, replacing M/s. MRR & Associates which resigned on May 21, 2026. This appointment aligns with Regulation 24A of the SEBI Listing Regulations and Section 204 of the Companies Act, 2013.

What the Numbers Show

The proactive disclosure of the Annual Report web-link underscores Aurobindo Pharma’s adherence to digital transparency norms under SEBI regulations. The emphasis on updating KYC details highlights a broader industry shift towards electronic dividend payments, reducing reliance on physical instruments. For shareholders, ensuring updated records is critical to receiving the confirmed ₹4 per share interim dividend without delay.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE406A01037/b3cb4f5b-80cd-4b19-b8df-63e744f70c28.pdf